Analyst Research

Report Title Price
Provider: S&P Capital IQ Quantitative Report
$127.00
Provider: Thomson Reuters Stock Report
$25.00
Provider: ValuEngine, Inc.
$25.00
Provider: Reuters Investment Profile
$20.00

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.

Synthetic Biologics Inc announces Rhonda Voskuhl to present trimesta phase ii multiple sclerosis clinical trial results


Monday, 10 Feb 2014 07:00am EST 

Synthetic Biologics Inc:Says Rhonda Voskuhl, the lead investigator of the Phase II clinical trial evaluating its oral estriol product candidate, Trimesta, for the treatment of relapsing-remitting multiple sclerosis, will present topline results at the American Academy of Neurology's (AAN) 66thAnnual Meeting in Philadelphia.Says the abstract titled, A Combination Trial of Estriol Plus Glatiramer Acetate in Relapsing-Remitting Multiple Sclerosis, will be presented as part of the AAN Emerging Science program during two sessions.Says Trimesta (oral estriol) is being evaluated in combination with Copaxone (glatiramer acetate injection) in a randomized, double-blind, placebo-controlled Phase II clinical trial for the treatment of relapsing-remitting MS in women.Says patients in this Phase II relapsing-remitting MS trial completed their final 24-month visit during Jan 2014.Says the primary outcome measure for the study is the annualized rate of relapse between the placebo and treated groups, an accepted FDA-approvable endpoint in MS. 

Company Quote

1.58
-0.19 -10.73%
24 Oct 2014